A female in her 60's was simultaneously diagnosed with stage I triple-negative left breast cancer and stage I NSCLC of the left lung.
The patient had received 6400 cGy and carboplatin-paclitaxel-pembrolizumab for their NSCLC lung cancer 6 months prior, with a mean heart dose 1490 cGy, mean LAD 925 cGy & left lung V20 = 33%.
The breast tumor grew slightly despite the systemic therapy, and adjuvant Xeloda is planned. All margins were >5 mm.
Thank you--this is exactly what I wound up telling...